News

Industry Insights

From Reactive to Proactive: Bridging the PMS-to-Design Gap in MedTech

A CAHIR Solutions Blog | MedTech Pulse | June 2026

Summary

This blogpost "From Reactive to Proactive: Bridging the PMS-to-Design Gap in MedTech" outlines a critical weakness in the medical device industry where post-market surveillance (PMS) data, such as complaints and adverse events, does not effectively flow back to design and engineering teams, creating a reactive system that addresses issues only after they occur. This disconnect stems from organizational silos between quality/regulatory and product teams, even though regulations like the EU MDR mandate that PMS be used as a proactive design input. To close this gap, we propose adopting an enterprise-wide discipline called Closed-Loop Quality (CLQ).

This requires five key operational steps: establishing a "digital thread" to unify fragmented data, redesigning PMS objectives to answer design improvement questions, using advanced analytics to turn complaint data into early intelligence, leveraging Post-Market Clinical Follow-up (PMCF) as a design research engine, and wiring PMS findings directly into formal risk management and Corrective and Preventive Action (CAPA) systems to ensure traceable design changes.

Ultimately, moving PMS from a compliance task to a continuous intelligence feed is described as both an organizational and technical shift that provides a competitive advantage.

The Gap No One Talks About — Until a Recall Forces the Conversation

Every medtech company has a complaint handling system. Most have some version of a PMS plan. What far fewer companies have is a living, functioning bridge between the signals buried in that post-market data and the engineers, designers, and product managers who can actually do something with it.

Survey data suggests that fewer than half of medical device manufacturers can connect what they learn from post-market surveillance data back to the rest of the engineering lifecycle. That is a striking number given how much regulatory effort goes into building PMS systems in the first place — and it represents one of the most consequential blind spots in modern medtech product development.

The good news: the gap is addressable. Closing it requires a deliberate framework, cross-functional discipline, and the right tooling. This post lays out how to do that practically.

Why the Reactive-Proactive Divide Exists

Post-market surveillance has historically been built around passive, event-driven inputs: adverse event reports, complaint forms, MDR submissions, and field service records. These reactive sources remain important — and are legally required — but they share a critical limitation: they tell you what went wrong after a patient experienced it.

The EU MDR uses the phrase "proactively collect and systematically gather, record and analyze relevant data" four times across Articles 83, 2(60), and 2(63). Yet in practice, notified body reviewers consistently flag insufficient proactive data collection as one of the most common PMS gaps. The reason is cultural as much as technical: quality and regulatory teams own PMS, while product and engineering teams own design. These groups often operate in functional silos with limited structured communication.

The result is a one-way information flow. PMS data flows toward compliance functions and stops there. It rarely completes the loop back to the people who can reshape a device's future versions.

What a Closed-Loop PMS System Actually Looks Like

Closing the loop is not a single software purchase or a new SOP. It is an enterprise-wide discipline — sometimes called Closed-Loop Quality (CLQ) — that connects pre-market and post-market lifecycle phases through shared data architecture, cross-functional processes, and clear ownership.

EU MDR Article 83 and Article 78 (IVDR) explicitly require that PMS data be used not just for compliance reporting but for:

Updating the risk-benefit assessment and improving risk management
Updating design and manufacturing information, instructions for use, and labeling
Updating the clinical evaluation
Identifying opportunities to improve usability, performance, and safety
Identifying and reporting trends

In other words, the regulation itself frames PMS as a design input — not just a quality output. The gap exists because most quality systems were built before this framing took hold.

The Five Connections That Must Be Made

For PMS data to reliably influence product design, five operational connections need to be in place:

Connected and Software-Driven Devices: A Higher Bar

For Software as a Medical Device (SaMD) and connected hardware platforms, the PMS-to-design loop must operate faster and with greater precision. Regulators now expect continuous, not annual, real-world performance monitoring for AI and software-driven devices. Performance drift — such as an AI diagnostic tool generating increased false positives after hospitals change imaging protocols — must be detectable, investigable, and correctable with a documented validation trail.

Real-time device usage analytics, enabled by tools embedded in connected hardware, provide more accurate and objective post-market usability data than traditional complaint-based systems alone. This data can surface use-related design gaps — interaction patterns, error rates, workflow friction — that would never appear in a formal complaint and would never make it into a traditional PMS report.

For software platforms in particular, every design change including bug fixes, patches, and AI model updates must be documented, validated, and tied back to the PMS signal that triggered it. This creates a traceable chain from real-world observation to design decision to validated release — the closed loop in its most complete form.

Where CAHIR Solutions Fits

CAHIR solutions partners with and supports medtech innovators in providing a comprehensive framework, detailed roadmaps, step-by-step guidance, organizational structure change management, and custom process automation for building exactly this kind of connected, design-informed PMS program unique to your device and device pipeline.

The specific leverage points are:

Centralizing PMS data intake across complaints, service records, adverse events, and PMCF sources into a single, structured view — eliminating the fragmentation that prevents cross-functional analysis
Automating trend detection and signal escalation so that design-relevant patterns surface in days rather than quarters
Connecting PMS outputs to risk management and CAPA workflows, ensuring that field intelligence reaches the people and processes that can act on it
Maintaining audit-ready documentation across the full PMS-to-design loop, from initial signal to verified corrective action
Supporting PMCF planning and execution as a structured design research engine, not just a regulatory filing

The goal is to help innovators move from a model where PMS is a compliance obligation that runs parallel to product development — to one where PMS is a continuous intelligence feed that makes every next-generation product safer, more effective, and faster to market.

Closing Thought

The medtech companies that will lead the next decade are not the ones with the most complaints — they are the ones that have built the most effective systems for learning from them. Post-market surveillance, done well, is the most honest feedback channel a device company has. Closing the loop between what the field reveals and what the design team builds is not just a compliance upgrade. It is a competitive advantage.